- EANM3
- Cancers · 2
- IAEA2
- SNMMI + EANM) · 1
- SNMMI + EANM · 1
- EANM + SNMMI · 1
- IAEA + EANM + SNMMI · 1
- IAEA 主導、EANM/SNMMI 專家共同 · 1
- EANM Dosimetry Committee1
- SNMMI1
放射性核素治療原理1 份
- EANM position paper on the role of radiobiology in nuclear medicine
碘-131 甲狀腺癌治療1 份
- SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer
鐳-223 骨轉移治療1 份
- SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases
鎦-177攝護腺特異膜抗原治療1 份
- Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy
鎦-177體抑素受體神經內分泌瘤治療1 份
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
釔-90選擇性體內放射治療1 份
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds
放射免疫治療1 份
- Radiometabolic Therapy in Lymphoma: From Radioimmunotherapy to Emerging Theranostic and Combination Strategies
診療合一概念1 份
- Guiding principles on the education and practice of theranostics
正子造影腫瘤診斷分期1 份
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
治療劑量學與輻射劑量評估1 份
- EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
治療後輻射防護與隔離1 份
- IAEA Safety Reports Series No. 63 — Release of Patients After Radionuclide Therapy
放射性藥物調製與品管1 份
- IAEA-TECDOC-1856 — Quality Control in the Production of Radiopharmaceuticals
甲狀腺癌碘治療前準備1 份
- The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
核種治療副作用處置1 份
- Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Radioligand Therapy
使用 Google 帳號登入,第一次登入時選擇科別即可開始;已經在用?直接登入
